Wells Fargo’s VITAE PHARMACEUTICALS INC COMMON STOCK VTAE Stock Holding History

Wells Fargo’s Portfolio VTAE Stock Details VTAE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	–	Sell	-13,499	Closed	-$283K	–	6679
2016 Q3	$283K	Buy	13,499 +5,062	+60%	+$58.3K	﹤0.01%	4278
2016 Q2	$91K	Sell	8,437 -1,832	-18%	-$15.7K	﹤0.01%	4893
2016 Q1	$69K	Buy	10,269 +3,227	+46%	+$29.3K	﹤0.01%	5086
2015 Q4	$127K	Buy	7,042 +6,982	+11,637%	+$96.1K	﹤0.01%	4753
2015 Q3	$1K	Sell	60 -604	-91%	-$6.42K	﹤0.01%	6134
2015 Q2	$10K	Sell	664 -1,455	-69%	-$19.8K	﹤0.01%	5829
2015 Q1	$25K	Buy	+2,119	New	+$28.6K	﹤0.01%	5303

Wells Fargo's VTAE Position: Q4 2016 in Review

Wells Fargo sold out of VITAE PHARMACEUTICALS INC COMMON STOCK (VTAE) in Q4 2016, closing a stake of 13,499 shares — an estimated $283K sold.

Wells Fargo first reported a position in VTAE in Q1 2015 and held it in 7 quarters. The position peaked at $283K in Q3 2016. 0 funds tracked by Wall St. Rank hold VTAE as of Q4 2016.

Wells Fargo reported no remaining VITAE PHARMACEUTICALS INC COMMON STOCK position as of Q4 2016 after selling out during the quarter.
Wells Fargo sold 13,499 VITAE PHARMACEUTICALS INC COMMON STOCK shares in Q4 2016, an estimated $283K.
Wells Fargo first reported a position in VITAE PHARMACEUTICALS INC COMMON STOCK in Q1 2015 and held it in 7 quarters.
Wells Fargo's VITAE PHARMACEUTICALS INC COMMON STOCK position peaked at $283K in Q3 2016.
0 funds tracked by Wall St. Rank held VITAE PHARMACEUTICALS INC COMMON STOCK as of Q4 2016.

Based on Wells Fargo's 13F filing for Q4 2016, filed 1 Feb 2017.